MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
Compugen Ltd. Operating Cycle 2011-2026 | CGEN
Annual Operating Cycle Compugen Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 60.8 | 182 | - | - | - | 42 | 331 | 10.5 | 127 | 265 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 331 | 10.5 | 146 |
Quarterly Operating Cycle Compugen Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.6 | 45.6 | 45.6 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
7.85 K | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 7.69 | 1.39 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
130 | $ 0.6 | -2.83 % | $ 6.87 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Heron Therapeutics
HRTX
|
842 | $ 0.8 | 2.29 % | $ 133 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Incyte Corporation
INCY
|
145 | $ 91.13 | 0.38 % | $ 17.8 B | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Inovio Pharmaceuticals
INO
|
1.91 K | $ 1.6 | 0.95 % | $ 35.5 M | USA |
 |
Denali Therapeutics
DNLI
|
1.89 | $ 21.15 | 4.86 % | $ 3.48 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
185 | - | -5.98 % | $ 34.1 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.1 K | - | - | $ 2.18 B | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.8 | 0.08 % | $ 120 M | USA |